These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 33815743)

  • 1. Effect of sodium-glucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score-matched analysis of real-world data.
    Arai T; Atsukawa M; Tsubota A; Mikami S; Ono H; Kawano T; Yoshida Y; Tanabe T; Okubo T; Hayama K; Nakagawa-Iwashita A; Itokawa N; Kondo C; Kaneko K; Emoto N; Nagao M; Inagaki K; Fukuda I; Sugihara H; Iwakiri K
    Ther Adv Endocrinol Metab; 2021; 12():20420188211000243. PubMed ID: 33815743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of sodium glucose cotransporter-2 inhibitors on liver steatosis/fibrosis/inflammation and redox balance in non-alcoholic fatty liver disease.
    Bellanti F; Lo Buglio A; Dobrakowski M; Kasperczyk A; Kasperczyk S; Aich P; Singh SP; Serviddio G; Vendemiale G
    World J Gastroenterol; 2022 Jul; 28(26):3243-3257. PubMed ID: 36051336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antifibrotic effect and long-term outcome of SGLT2 inhibitors in patients with NAFLD complicated by diabetes mellitus.
    Arai T; Atsukawa M; Tsubota A; Mikami S; Haruki U; Yoshikata K; Ono H; Kawano T; Yoshida Y; Tanabe T; Okubo T; Hayama K; Nakagawa-Iwashita A; Itokawa N; Kondo C; Kaneko K; Nagao M; Inagaki K; Fukuda I; Sugihara H; Iwakiri K
    Hepatol Commun; 2022 Nov; 6(11):3073-3082. PubMed ID: 36039537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of sodium-glucose cotransporter-2 inhibitors and thiazolidinediones for management of non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Hameed I; Hayat J; Marsia S; Samad SA; Khan R; Siddiqui OM; Khan MO; Malik S; Fatima K; Fudim M; Krasuski RA
    Clin Res Hepatol Gastroenterol; 2023 May; 47(5):102111. PubMed ID: 36931466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SGLT2 inhibitors for improving hepatic fibrosis and steatosis in non-alcoholic fatty liver disease complicated with type 2 diabetes mellitus: a systematic review.
    Dwinata M; Putera DD; Hasan I; Raharjo M
    Clin Exp Hepatol; 2020 Dec; 6(4):339-346. PubMed ID: 33511282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium-Glucose Cotransporter-2 Inhibitors Ameliorate Liver Enzyme Abnormalities in Korean Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease.
    Euh W; Lim S; Kim JW
    Front Endocrinol (Lausanne); 2021; 12():613389. PubMed ID: 34177796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of sodium-glucose cotransporter 2 inhibitors on non-alcoholic fatty liver disease in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
    Xing B; Zhao Y; Dong B; Zhou Y; Lv W; Zhao W
    J Diabetes Investig; 2020 Sep; 11(5):1238-1247. PubMed ID: 32083798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Effects of Sodium-Glucose Cotransporter 2-Inhibitors on Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease or Steatohepatitis and Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials.
    Bica IC; Stoica RA; Salmen T; Janež A; Volčanšek Š; Popovic D; Muzurovic E; Rizzo M; Stoian AP
    Medicina (Kaunas); 2023 Jun; 59(6):. PubMed ID: 37374340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease.
    Shimizu M; Suzuki K; Kato K; Jojima T; Iijima T; Murohisa T; Iijima M; Takekawa H; Usui I; Hiraishi H; Aso Y
    Diabetes Obes Metab; 2019 Feb; 21(2):285-292. PubMed ID: 30178600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meta-analysis of the effect of sodium-glucose cotransporter 2 inhibitors on hepatic fibrosis in patients with type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease.
    Song T; Chen S; Zhao H; Wang F; Song H; Tian D; Yang Q; Qi L
    Hepatol Res; 2021 Jun; 51(6):641-651. PubMed ID: 33847462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sodium-glucose cotransporter-2 inhibitors improve FibroScan-aspartate aminotransferase scores in patients with nonalcoholic fatty liver disease complicated by type 2 diabetes.
    Ogawa Y; Nakahara T; Ando Y; Yamaoka K; Fujii Y; Uchikawa S; Fujino H; Ono A; Murakami E; Kawaoka T; Miki D; Yamauchi M; Tsuge M; Imamura M; Oka S
    Eur J Gastroenterol Hepatol; 2023 Sep; 35(9):989-996. PubMed ID: 37395206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: A common comorbidity associated with severe complications.
    Scheen AJ
    Diabetes Metab; 2019 Jun; 45(3):213-223. PubMed ID: 30708071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarkers for Assessing Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus on Sodium-Glucose Cotransporter 2 Inhibitor Therapy.
    Khaznadar F; Petrovic A; Khaznadar O; Roguljic H; Bojanic K; Kuna Roguljic L; Siber S; Smolic R; Bilic-Curcic I; Wu GY; Smolic M
    J Clin Med; 2023 Oct; 12(20):. PubMed ID: 37892698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ipragliflozin Ameliorates Liver Damage in Non-alcoholic Fatty Liver Disease.
    Miyake T; Yoshida S; Furukawa S; Sakai T; Tada F; Senba H; Yamamoto S; Koizumi Y; Yoshida O; Hirooka M; Kumagi T; Niiya T; Miyaoka H; Masanori A; Matsuura B; Hiasa Y
    Open Med (Wars); 2018; 13():402-409. PubMed ID: 30234161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography.
    Lai LL; Wan Yusoff WNI; Vethakkan SR; Nik Mustapha NR; Mahadeva S; Chan WK
    J Gastroenterol Hepatol; 2019 Aug; 34(8):1396-1403. PubMed ID: 30551263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sodium-glucose cotransporter-2 inhibitors improve liver enzymes in patients with co-existing non-alcoholic fatty liver disease: a systematic review and meta-analysis.
    Amjad W; Malik A; Qureshi W; Dennis B; Mumtaz M; Haider R; Jamal S; Jaura F; Ahmed A
    Prz Gastroenterol; 2022; 17(4):288-300. PubMed ID: 36514450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus.
    Seko Y; Sumida Y; Tanaka S; Mori K; Taketani H; Ishiba H; Hara T; Okajima A; Umemura A; Nishikawa T; Yamaguchi K; Moriguchi M; Kanemasa K; Yasui K; Imai S; Shimada K; Itoh Y
    Hepatol Res; 2017 Sep; 47(10):1072-1078. PubMed ID: 27925353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD care.
    Hofmann WP; Buggisch P; Schubert L; Dikopoulos N; Schwenzer J; Muche M; Felten G; Heyne R; Ingiliz P; Schmidt A; Stein K; Wedemeyer H; Berg T; Wiegand J; Lammert F; Zeuzem S; Schattenberg JM
    JHEP Rep; 2020 Dec; 2(6):100168. PubMed ID: 32964201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial.
    Taheri H; Malek M; Ismail-Beigi F; Zamani F; Sohrabi M; Reza Babaei M; Khamseh ME
    Adv Ther; 2020 Nov; 37(11):4697-4708. PubMed ID: 32975679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease.
    Aso Y; Kato K; Sakurai S; Kishi H; Shimizu M; Jojima T; Iijima T; Maejima Y; Shimomura K; Usui I
    Int J Clin Pract; 2019 May; 73(5):e13335. PubMed ID: 30810254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.